Get the Stockscreener App
434.19
1.16%
4.97
After Hours:
433.16
-1.03
-0.24%
Vertex Pharmaceuticals Inc stock is traded at $434.19, with a volume of 1.36M.
It is up +1.16% in the last 24 hours and up +6.47% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$429.22
Open:
$429.69
24h Volume:
1.36M
Relative Volume:
0.89
Market Cap:
$111.32B
Revenue:
$11.74B
Net Income/Loss:
$3.68B
P/E Ratio:
30.60
EPS:
14.1888
Net Cash Flow:
$3.34B
1W Performance:
+4.12%
1M Performance:
+6.47%
6M Performance:
-1.18%
1Y Performance:
-11.39%
1-Day Range:
$425.46
$435.94
1-Week Range:
$406.67
$435.94
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
434.19 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.72 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.74 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.89 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
377.47 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedJuly 2025 Technicals & Stepwise Entry/Exit Trade Alerts - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataPortfolio Gains Report & Low Risk High Win Rate Stock Picks - newser.com
Published on: 2025-11-12 14:18:38 - newser.com
Published on: 2025-11-12 11:06:37 - newser.com
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space - BioSpace
Vertex highlights growing Medicaid coverage for non-opioid painkiller Journavx (VRTX:NASDAQ) - Seeking Alpha
Transcript : Vertex Pharmaceuticals Incorporated Presents at UBS Global Healthcare Conference 2025, Nov-09-2025 through Nov-12-2025 - MarketScreener
Will Vertex Pharmaceuticals Incorporated benefit from macro trendsPortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingDip Buying & Free Fast Gain Swing Trade Alerts - newser.com
The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail
Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development - TipRanks
Vertex stock holds steady as Stifel maintains $445 price target By Investing.com - Investing.com UK
Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating - TipRanks
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Vertex Pharma Q3 2025 Earnings: $3.08B Revenue, EPS $4.80, Updates GuidanceNews and Statistics - IndexBox
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call - The Globe and Mail
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Reactions & Daily Profit Focused Stock Screening - newser.com
Vertex Pharmaceuticals (VRTX) Reports Promising Results from RUB - GuruFocus
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessJuly 2025 Fed Impact & AI Powered Market Entry Strategies - newser.com
Vertex Unveils Positive 48-Week Data For Povetacicept In IgAN And PMN - Nasdaq
Transcript : Vertex Pharmaceuticals IncorporatedSpecial Call - MarketScreener
Vertex reports promising 48-week data for povetacicept in kidney diseases - Investing.com Canada
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week - Business Wire
VRTX: UBS Adjusts Vertex Pharmaceuticals Price Target to $546 | VRTX Stock News - GuruFocus
UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating - MarketScreener
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceShort Setup & Capital Efficient Trade Techniques - newser.com
Top Biotech Stocks To Follow TodayNovember 3rd - MarketBeat
Nasdaq, Vertex CEOs talk biotech public markets, AI at Boston event - The Business Journals
Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options - Nasdaq
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
Will Vertex Pharmaceuticals Incorporated bounce back from current supportTake Profit & Verified Swing Trading Watchlist - newser.com
Will Vertex Pharmaceuticals Incorporated stock maintain dividend yieldJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - fcp.pa.gov.br
Promising Biotech Stocks To Watch NowNovember 4th - MarketBeat
Royal Bank Of Canada Issues Pessimistic Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? - Yahoo Finance
Long term hold vs stop loss in Vertex Pharmaceuticals Incorporated2025 Trade Ideas & AI Based Buy/Sell Signal Reports - newser.com
Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Milestone Asset Management LLC Invests $1.13 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bryce Point Capital LLC Purchases 710 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipelineWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Vertex Pharma's Painkiller Collapse Sends Shockwaves—But One Drug Could Save It All! - Smartkarma
Huntington National Bank Has $14.88 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):